As China gears up to the possible launch of its first vaccines against the coronavirus, supported by clearer regulations, many see the candidates as promising and cost-effective, although they may need more convincing data to be widely adopted. Relatively low projected per dose costs are generating interest in trials in multiple countries.
Amid a global race to launch the first vaccine against the coronavirus and after Russia became the first nation to approve its candidate - albeit based on only small trials and limited data - many are now turning their attention to China, a front-runner with multiple vaccines now in final-stage development.
One Chinese health official recently disclosed that as early as 22 July, the country had issued emergency use authorizations (EUAs)...
Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
European health systems already pay far too much for new medicines and payers will not accept higher prices to compensate for lower US prices, according to Anja Schiel, from NOMA, the Norwegian health technology assessment body.
In a somewhat surprising move, President Trump’s Federal Trade Commission is continuing a crusade to delist improper listings from the FDA’s Orange Book. Law firm Polsinelli’s chair Chad Landmon discussed the impact of the move on the generic drug industry.
